Richard Davis
Directeur/Bestuurslid bij NANEXA AB
Profiel
Richard Jon Davis is currently an Independent Director at Nanexa AB since 2022 and the Chief Operating Officer at Nouscom AG since 2020.
Previously, he served as the Chief Executive Officer at Trino Therapeutics Ltd.
from 2014 to 2015.
He also held a position as a Non-Executive Director at Kymab Ltd.
and worked as a Manager-Healthcare Investment at The Wellcome Trust Ltd.
Dr. Davis obtained his undergraduate and doctorate degrees from the University of Leicester.
Actieve functies van Richard Davis
Bedrijven | Functie | Begin |
---|---|---|
NANEXA AB | Directeur/Bestuurslid | 01-01-2022 |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Operationeel Directeur | 23-05-2022 |
Eerdere bekende functies van Richard Davis
Bedrijven | Functie | Einde |
---|---|---|
Trino Therapeutics Ltd.
Trino Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Trino Therapeutics Ltd. operates as a drug discovery and development company. It focuses on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease and other inflammatory indications. The company was founded by Neil Howard Frankish and Helen Sheridan in 1999 and is headquartered in Dublin, Ireland. | Algemeen Directeur | - |
The Wellcome Trust Ltd.
The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK. | Corporate Officer/Principal | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Directeur/Bestuurslid | - |
Opleiding van Richard Davis
University of Leicester | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NANEXA AB | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Trino Therapeutics Ltd.
Trino Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Trino Therapeutics Ltd. operates as a drug discovery and development company. It focuses on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease and other inflammatory indications. The company was founded by Neil Howard Frankish and Helen Sheridan in 1999 and is headquartered in Dublin, Ireland. | Health Technology |
The Wellcome Trust Ltd.
The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK. | Miscellaneous |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Health Technology |